← ANALYST RATINGS · TIPRANKS
Assembly Biosciences (ASMB): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $48.33, the highest $52.00, the lowest $43.00. The average is +140.6% from the last price of $20.09.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $21.50 → $21.00−2.3% | Hold | +4.5% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $22.00 → $21.50−2.3% | Hold | +7.0% | Downgrade | 17.10.26on TipRanks 17:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $20.50 → $20.00−2.4% | Hold | −0.4% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $20.00 → $19.50−2.5% | Hold | −2.9% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $21.00 → $20.50−2.4% | Hold | +2.0% | Downgrade | 17.10.26on TipRanks 17:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $21.00 → $20.50−2.4% | Hold | +2.0% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| Patrick Trucchio★★★★★★★★★★#79 · hits 58% · avg +37.9% | H.C. Wainwright | $50.00 | Buy | +148.9% | Reiterated | 08.10.26on TipRanks Oct 9 06:11 | −0.1%next day +2.5% · 5 days −9.6% | ↗ |
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $52.00 | Buy | +158.8% | Initiated | 01.09.26on TipRanks 05:15 | +5.3%next day +3.9% · 5 days −6.6% | ↗ |
| Salim Syed★★★★★★★★★★#7609 · hits 44% · avg +0.2% | Mizuho Securities | $45.00 → $53.00+17.8% | Buy | +163.8% | Reiterated | 31.08.26on TipRanks 10:30 | −1.0%next day +5.3% · 5 days +5.0% | ↗ |
| Vamil Divan★★★★★★★★★★#458 · hits 59% · avg +13.5% | Guggenheim | $43.00 | Buy | +114.0% | Reiterated | 16.08.26on TipRanks Aug 17 07:32 | −8.4%next day +7.7% · 5 days +18.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Assembly Biosciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $49.50 at a price of $23.49 (+110.7%); now: $49.50 at $20.09 (+146.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 2 | 3 | 4 |
| Buy | 2 | 2 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.66 (from $-1.12 to $-0.26). Last quarter: $-0.20.
Sales
Next quarter’s sales estimate — $9M (from $5M to $12M). Last quarter: $13M.
Best top-analyst consensus in the sector · Healthcare
About Assembly Biosciences
- CEO: Jason A. Okazaki
- Employees: 73
- Two Tower Place, South San Francisco, CA, 94080, US
- www.assemblybio.com
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Data from the stock’s TipRanks forecast page, read 61 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗